Carter BloodCare

To: Carter BloodCare Customers
From: Hospital Relations Department
Date: May 26, 2021
Re: Updated Circular of Information and Zika Testing Update

Background

On May 12, 2021, the FDA's July 2018 ZIKV Testing Guidance was withdrawn because the agency has determined that testing for ZIKV, or pathogen reduction as an alternative to testing for ZIKV, is not necessary because ZIKV is no longer a Relevant Transfusion-Transmitted Infection (RTTI).

Impact to Client

Please find attached the updated electronic version of the Circular of Information specific for Carter BloodCare. This version includes the required update to discontinue ZIKV testing by adding the following statement "Blood components collected between December 3, 2018 - June 7, 2021 were tested with a licensed nucleic acid test (NAT) for Zika Virus RNA and found to be nonreactive."

Additionally, the electronic version can be accessed and viewed at the following link:

Direct link: Carter BloodCare Circular of Information

Or by going to Carterbloodcare.org, click on "Hospital Partners" and then click on "Licenses & Accreditations."

Carter Bloodcare is currently undergoing the process of discontinuing Zika virus (ZIKV) testing. We will communicate future updates relevant to this process as applicable.